Skip to ContentSkip to Navigation
Over ons Praktische zaken Waar vindt u ons prof. dr. G.A. Huls

Publicaties

Donor lymphocyte infusions after HLA-identical hematopoietic stem cell transplantation with post-transplant cyclophosphamide in acute myeloid leukemia patients

High expression of signal regulatory protein beta 2 marks a favourable prognostic AML subgroup and associates with increased sensitivity to phagocytosis

Increased Clonal Hematopoiesis in Long-term Survivors of Pediatric Hematopoietic Cell Transplantation

Long-term survival can be achieved in a significant fraction of older patients with core-binding factor acute myeloid leukemia treated with intensive chemotherapy

Midostaurin added to 10-day decitabine, for patients unfit for intensive chemotherapy with AML and higher risk MDS, irrespective of FLT3 mutational status, does not improve outcome

The association between hospital volume and overall survival in adult AML patients treated with intensive chemotherapy

A 4-gene prognostic index for enhancing acute myeloid leukaemia survival prediction

Acute promyelocytic leukaemia in low-income and middle-income countries: a Brazilian experience

Bayesian interim analysis for prospective randomized studies: reanalysis of the acute myeloid leukemia HOVON 132 clinical trial

Beyond The Skin: B Cells in Pemphigus Vulgaris, Tolerance and Treatment

Pers/media

Professor Dr. Gerwin Huls te gast bij Nutsdepartement Vlagtwedde

Professor Dr. Gerwin Huls te gast bij Nutsdepartement Vlagtwedde

Nationaal Groeifonds investeert in UMCG-studies om ontwikkeling kankermedicijnen te versnellen